The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2016
Price : $35 *
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms dPEP
- 25 May 2016 Status changed from active, no longer recruiting to completed.
- 16 Nov 2015 Planned End Date changed from 1 Jun 2016 to 1 Feb 2016, as per ClinicalTrials.gov record.
- 16 Nov 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Nov 2015, as per ClinicalTrials.gov record.